Market capitalization | $95.78m |
Enterprise Value | $78.79m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.12 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-41.07m |
Free Cash Flow (TTM) Free Cash Flow | $-29.09m |
Cash position | $17.91m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
3 Analysts have issued a Citius Pharmaceuticals Inc forecast:
3 Analysts have issued a Citius Pharmaceuticals Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.21 -0.21 |
11%
11%
|
|
EBITDA | -41 -41 |
20%
20%
|
EBIT (Operating Income) EBIT | -41 -41 |
20%
20%
|
Net Profit | -38 -38 |
25%
25%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
Head office | United States |
CEO | Leonard Mazur |
Employees | 22 |
Founded | 2007 |
Website | www.citiuspharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.